Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMO-103 in metastatic pancreatic cancer
NCT06059001Phase 1Active, not recruiting
- Sponsor
- Peptomyc
- Start
- Aug 2023
- Primary completion
- May 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OMO-103 in pancreatic cancer (PC), sponsored by Peptomyc. Primary endpoints: Adverse Events at 2 years and Serious Adverse Events at 2 years. Started Aug 2023; status: active, not recruiting.
02
Drugs
OMO-103
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06059001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06059001.